Degludec Articles
Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg
11 February 2013
FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks
6 November 2012
Highlights of American Diabetes Association meeting
11 June 2012
Novo Nordisk starts year with 15% net profits hike
30 April 2012
Positive Ph III results for Novo Nordisk's degludec; US advocacy calls for Victoza's withdrawal
23 April 2012
Novo Nordisk files for EU approval of ultra-long-acting insulins Degludec and DegludecPlus
28 September 2011
New data on Boehringer Ingelheim’s linagliptin, Novo Nordisk’s degludec and Merck & Co’s Januvia presented at EASD
23 September 2010
Showing 1-18 of 18 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
